Serum Tenascin-C Concentration in Patients With Acute Coronary Syndrome

Change of Serum Tenascin-C Concentration and the Relationship With Hs-CRP，cTnI and Prognosis in Patients With Acute Coronary Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02767960

Enrollment

183

Registered

2016-05-11

Start date

2016-05-31

Completion date

2017-07-31

Last updated

2017-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

Tenascin-C

Brief summary

This study valuates the serum Tenascin-C concentration in patients with acute coronary syndrome.

Detailed description

It is found that Tenascin-C plays an important role in ventricular remodeling, heart failure, aortic dissection, rheumatic heart disease and other cardiovascular diseases, which may be a new marker for the diagnosis and prognosis prediction of these diseases. However, there is few relevant studies about the Tenascin-C concentration in patients with acute coronary syndrome.This study valuates the serum Tenascin-C concentration in patients with acute coronary syndrome.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

.diagnosed as acute coronary syndrome,including STEMI,non-STEMI,and UAP. * with left ventricular ejection fraction（LVEF）\>=45% * written informed consents are obtained * admitted within 24 hours after chest pain attacked

Exclusion criteria

* complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy * complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction * with acute or chronic infection, surgery or trauma in the last month * secondary hypertension, severe liver dysfunction,severe renal insufficiency * with abnormal thyroid function or allergy to iodine agent * refusal to sign the informed consent

Design outcomes

Primary

Measure	Time frame	Description
Serum Tenascin-C concentration	12 months	Serum Tenascin-C concentration in ng/ml

Secondary

Measure	Time frame	Description
Relationship between Tenascin-C and high sensitive C reaction protein (hs-CRP) concentration	12 months	With or without association between them
Relationship between Tenascin-C and Troponin-I (Tn-I) concentration	12 months	With or without association between them
MACEs during 12-month follow-up	12 months	All major adverse cardiac events( MACEs) including death, myocardial infarction, angina, heart failure are recorded.

Countries

China

Outcome results